Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?

 
• By Joseph Haas

ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.

Risk Reduction words on puzzle pieces to illustrate a solution or mitigation of danger, hazard, liability or injury
Like Repatha, Praluent now has CV outcomes data in its US label.

More from Cardiovascular

More from Therapy Areas